Mia's Feed
Medical News & Research

Effective System-Wide Initiative Enhances Treatment for Opioid Use Disorder

Effective System-Wide Initiative Enhances Treatment for Opioid Use Disorder

Share this article

A nationwide system-wide program has shown significant improvements in treating opioid use disorder by expanding access to medication-assisted treatment within healthcare settings, reducing hospital readmissions, and fostering coordinated care. Learn how Ohio State’s innovative approach can serve as a model for other health systems.

2 min read

A comprehensive, system-wide approach to providing medication-based treatment has demonstrated promising results in managing opioid use disorder (OUD) across healthcare settings, according to recent research from The Ohio State University. This initiative emphasizes routine offering and initiation of medications such as buprenorphine and methadone to patients with OUD, aiming to reduce associated health risks and improve outcomes.

Published in the journal Psychological Services, the study details how Ohio State's healthcare system implemented a coordinated effort starting in 2019 to expand access to medication-assisted treatment (MAT) within emergency, inpatient, and outpatient environments. Prior to this effort, many patients struggled to access these treatments outside specialized opioid treatment programs, which often posed logistical barriers, especially for those hospitalized for other health issues.

Over the first four years, the program successfully initiated medication treatment more than 4,900 times, leading to improved health outcomes and fewer hospital readmissions. Experts involved in the study highlighted that developing innovative, multidisciplinary care strategies is essential for addressing complex patient populations effectively.

One of the key challenges identified was the inconsistent understanding of OUD among healthcare providers not specialized in behavioral health. Addressing this gap through education and leadership support has been crucial in enhancing treatment success. Emergency departments have been recognized as vital points for early intervention, as many patients presenting with opioid withdrawal symptoms may be more receptive to medication during hospitalization.

The Ohio State team underscored that leadership commitment and seamless coordination among various healthcare units are fundamental to such programs' success. Supporting staff, including peer supporters, social workers, and care coordinators, continuously foster an environment conducive to treatment engagement.

This approach's positive results suggest that other hospital systems could adopt similar strategies to improve access to medication for OUD, ultimately leading to better patient outcomes and reduced healthcare burdens.

Source: https://medicalxpress.com/news/2025-07-wide-opioid-disorder.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Impact of the No Surprises Act: Significant Reduction in Patients' Out-of-Pocket Medical Expenses

A new study finds that the No Surprises Act enacted in 2022 has significantly lowered patients' out-of-pocket healthcare costs, saving nearly $600 annually per individual and reducing surprise billing among insured adults.

Low-Cost Educational Interventions Effectively Reduce Alcohol Consumption During Pregnancy

A study reveals that brief, low-cost educational materials can effectively improve knowledge and attitudes about alcohol use during pregnancy, helping to prevent fetal alcohol spectrum disorder and related harms.

U.S. Panel Endorses New RSV Antibody Treatment for Children Amid Administrative Changes

An advisory panel has recommended a new antibody treatment for RSV in infants, marking a significant step in pediatric respiratory illness prevention amidst recent public health leadership changes.

Organ-Specific Inflammation Mimics Relapse in CAR T-Cell Therapy Remission

New research identifies organ-specific toxicity, LICATS, as a self-limiting side effect of CAR T-cell therapy in autoimmune diseases, aiding better diagnosis and management.